Efficacy Study of Azithromycin-based Therapy for Bronchiolitis Obliterans

This is an interventional treatment trial for Graft vs Host Disease focused on measuring Allogeneic hematopoietic cell transplantation, Graft versus host disease, Bronchiolitis obliterans, Azithromycin, N-acetylcystein, Fluticasone, Inhaled steroid Read More

Inclusion Criteria:

• Patients who previously received allogeneic hematopoietic cell transplantation due to hematologic malignancy, bone marrow failure syndrome, and other compatible disease.
• Patients who are diagnosed as bronchiolitis obliterans (BO) according to the NIH diagnostic guideline which is suggested as below.
• Patients should be 15 years of age or older, but younger than 75 years.
• Patients should have estimated life expectancy of more than 3 months.
• Patients must have adequate hepatic function (bilirubin less than 3.0 ㎎/㎗, AST and ALT less than three times the upper normal limit).
• Patients must have adequate renal function (creatinine less than 2.0 ㎎/㎗).

Exclusion Criteria:

• Presence of significant active infection
• Presence of uncontrolled bleeding
• Any coexisting major illness or organ failure
• Patients with a psychiatric disorder or mental deficiency severe as to make compliance with the treatment unlike, and making informed consent impossible.
• Nursing women, pregnant women, women of childbearing potential who do not want adequate contraception
• Patients with a diagnosis of prior malignancy unless disease-free for at least 5 years following therapy with curative intent (except curatively treated nonmelanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia)